Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320:1360–72. https://doi.org/10.1001/jama.2018.13103.

Article  PubMed  Google Scholar 

Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10:2857. https://doi.org/10.3390/cells10112857.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3–18.

Article  CAS  PubMed  Google Scholar 

Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73:924–39. https://doi.org/10.1002/acr.24596.

Article  PubMed  Google Scholar 

Huang J, Fu X, Chen X, et al. Promising therapeutic targets for treatment of rheumatoid arthritis. Front Immunol. 2021;12:686155. https://doi.org/10.3389/fimmu.2021.686155.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonelli M, Scheinecker C. How does abatacept really work in rheumatoid arthritis? Curr Opin Rheumatol. 2018;30:295–300. https://doi.org/10.1097/bor.0000000000000491.

Article  CAS  PubMed  Google Scholar 

Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519–31. https://doi.org/10.2147/jir.s219586.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morinobu A. JAK inhibitors for the treatment of rheumatoid arthritis. Immunol Med. 2020;43:148–55. https://doi.org/10.1080/25785826.2020.1770948.

Article  PubMed  Google Scholar 

Migliore A, Pompilio G, Integlia D, et al. Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211002682. https://doi.org/10.1177/1759720x211002682.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513–24. https://doi.org/10.1016/s0140-6736(18)31116-4.

Article  CAS  PubMed  Google Scholar 

Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78:1454–62. https://doi.org/10.1136/annrheumdis-2019-215764.

Article  CAS  PubMed  Google Scholar 

Fleischmann RM, Blanco R, Hall S, et al. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. Ann Rheum Dis. 2021;80:432–9. https://doi.org/10.1136/annrheumdis-2020-218412.

Article  CAS  PubMed  Google Scholar 

Lin YJ, Anzaghe M, Schulke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9:880. https://doi.org/10.3390/cells9040880.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garbers C, Heink S, Korn T, et al. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17:395–412. https://doi.org/10.1038/nrd.2018.45.

Article  CAS  PubMed  Google Scholar 

CorEvitas. Rheumatoid arthritis registry. https://www.corevitas.com/registry/rheumatoid-arthritis. Accessed 23 Mar 2022.

Kremer JM. The CORRONA database. Autoimmun Rev. 2006;5(1):46–54. https://doi.org/10.1016/j.autrev.2005.07.006.

Article  PubMed  Google Scholar 

Anderson JK, Zimmerman L, Caplan L, et al. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken). 2011;63:S14-36. https://doi.org/10.1002/acr.20621.

Article  PubMed  Google Scholar 

Greenwood MC, Doyle DV, Ensor M. Does the Stanford Health Assessment Questionnaire have potential as a monitoring tool for subjects with rheumatoid arthritis? Ann Rheum Dis. 2001;60:344–8. https://doi.org/10.1136/ard.60.4.344.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63:S240–52. https://doi.org/10.1002/acr.20543.

Article  PubMed  Google Scholar 

Tubach F, Ravaud P, Martin-Mola E, et al. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: results from a prospective multinational study. Arthritis Care Res (Hoboken). 2012;64:1699–707. https://doi.org/10.1002/acr.21747.

Article  CAS  PubMed  Google Scholar 

Kitchen H, Hansen BB, Abetz L, et al. Patient-reported outcome measures for rheumatoid arthritis: minimal important differences review [abstract]. In: 2013 ACR/ARHP annual meeting. https://acrabstracts.org/abstract/patient-reported-outcome-measures-for-rheumatoid-arthritis-minimal-important-differences-review/. Accessed 6 Apr 2022.

Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S263–86. https://doi.org/10.1002/acr.20579.

Article  PubMed  Google Scholar 

Khanna D, Pope JE, Khanna PP, et al. The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. J Rheumatol. 2008;35:2339–43. https://doi.org/10.3899/jrheum.080375.

Article  PubMed  PubMed Central  Google Scholar 

Rubbert-Roth A, Aletaha D, Devenport J, et al. Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. Rheumatology (Oxford). 2021;60:682–91. https://doi.org/10.1093/rheumatology/keaa259.

Article  CAS  PubMed  Google Scholar 

Aletaha D, Funovits J, Ward MM, et al. Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline. Arthritis Rheum. 2009;61:313–20. https://doi.org/10.1002/art.24282.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strand V, Gossec L, Proudfoot CWJ, et al. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2018;20:129. https://doi.org/10.1186/s13075-018-1614-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:198. https://doi.org/10.1186/s13075-016-1096-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toth L, Juhasz MF, Szabo L, et al. Janus kinase inhibitors improve disease activity and patient-reported outcomes in rheumatoid arthritis: a systematic review and meta-analysis of 24,135 patients. Int J Mol Sci. 2022;23:1246. https://doi.org/10.3390/ijms23031246.

Article  PubMed  PubMed Central  Google Scholar 

Lee YH, Bae SC. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2016;19:1103–11. https://doi.org/10.1111/1756-185x.12822.

Article  CAS  PubMed  Google Scholar 

Choy E, Freemantle N, Proudfoot C, et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor alpha inhibitors: systematic literature review and network meta-analyses. RMD Open. 2019;5: e000798. https://doi.org/10.1136/rmdopen-2018-000798.

Article  PubMed  PubMed Central  Google Scholar 

Aletaha D, Maa JF, Chen S, et al. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78:1609–15. https://doi.org/10.1136/annrheumdis-2018-214918.

Article  CAS  PubMed  Google Scholar 

Kilcher G, Hummel N, Didden EM, et al. Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. Rheumatology (Oxford). 2018;57:354–69. https://doi.org/10.1093/rheumatology/kex394.

Article